Cue Biopharma is trading 5.77% down at $26.61 after no verified company-specific catalyst was identified for August 12, 2026.
- Latest official company news concerns the August 3 appointment of CFO James M. Ahlers and the CUE-221 investigational new drug submission, rather than a new announcement today.
- The decline runs counter to broader markets, which are higher, leaving the immediate reason unclear.